SG11201901077RA - Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof - Google Patents
Anti-tigit antibodies, anti-pvrig antibodies and combinations thereofInfo
- Publication number
- SG11201901077RA SG11201901077RA SG11201901077RA SG11201901077RA SG11201901077RA SG 11201901077R A SG11201901077R A SG 11201901077RA SG 11201901077R A SG11201901077R A SG 11201901077RA SG 11201901077R A SG11201901077R A SG 11201901077RA SG 11201901077R A SG11201901077R A SG 11201901077RA
- Authority
- SG
- Singapore
- Prior art keywords
- harokmim
- holon
- compugen
- international
- pvrig
- Prior art date
Links
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 1#111011110111010101111101 110 1 001111110110011111H11011111011 ill Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\"\" WO 2018/033798 Al 22 February 2018 (22.02.2018) WIP0 I PCT (51) (21) (22) (25) Filing Language: (26) (30) (71) (72) International Patent Classification: C07K 16/28 (2006.01) A61K 39/00 (2006.01) International Application Number: PCT/IB2017/001256 International Filing Date: 17 August 2017 (17.08.2017) Publication Language: Priority Data: 62/376,334 17 August 2016 (17.08.2016) 62/376,335 17 August 2016 (17.08.2016) 62/417,217 03 November 2016 (03.11.2016) 62/477,974 28 March 2017 (28.03.2017) 62/513,771 01 June 2017 (01.06.2017) 62/513,916 01 June 2017 (01.06.2017) 62/513,775 01 June 2017 (01.06.2017) 62/538,561 28 July 2017 (28.07.2017) Applicant: COMPUGEN LTD. [IL/IL]; 26 Harokmim Street, 5885849 Holon (IL). Harokmim c/o Compugen Ltd., 26 Harokmim Street, 5885849 Holon (IL). STAPLETON, Lance; c/o Compugen, Ltd., 26 St., 5885849 Holon (IL). DRAKE, Andrew, W.; c/o Holon Harokmim Compugen, Ltd., 26 Harokmim St., 5885849 (IL). GOZLAN, Yosi; c/o Compugen, Ltd., 26 St 5885849 Holon (IL). VAKNIN, Ilan; c/o , Compugen, English 26 Harokmim English o Compugen, Ltd., 26 Harokmim St 5885849 Holon (IL). TIRAN, 5885849 US gen, Ltd., 26 Harokmim St US TURI, US 5885849 US Ltd., 26 US Kyle; US Holon US 26 Harokmim US c/o Compugen, OPHIR, Eran; c/o Compugen, Ltd., 26 Harokmim St., Ltd., 26 Harokmim St 5885849 Holon (IL). , SAMEAH-GREENWALD, Shirley; c/o Compugen, Ltd., St 5885849 Holon (IL). DASSA, Liat; c/ , , Zohar; c/o Compugen, Ltd., 26 Harokmim St , Holon (IL). COJOCARU, Gad., S.; c/o Compu- 5885849 Holon (IL). KOT- , Maya; c/o Compugen, Ltd., 26 Harokmim St., Holon (IL). CHENG, Hsin-Yuan; c/o Compugen, Harokmim St 5885849 Holon (IL). HANSEN, , c/o Compugen, Ltd., 26 Harokmim St., 5885849 (IL). GILADI, David, Nisim; c/o Compugen, Ltd., St, 5885849 Holon (IL). SAFYON, Einav; Ltd., 26 Harokmim St, 5885849 Holon (IL). 5885849 Ltd., 26 Ltd., 26 Richard; San- Holon 5885849 Harokmim Holon (IL). PRESTA, Leonard; c/o Compugen, Harokmim St , 5885849 Holon (IL). THEOLIS, — = Inventors: WHITE, Mark; c/o Compugen Harokmim St., 5885849 Holon (IL). KUMAR, c/o Compugen, Ltd., 26 Harokmim St 5885849 , = (IL). DESAI, Radhika; c/o Compugen, Ltd., 26 St 5885849 Holon (IL). WALL, Patrick; c/o , _ deep; c/o Compugen Ltd., 26 Harokmim Street, = Holon (IL). CHAN, Christopher; c/o Compugen Harokmim Street, 5885849 Holon (IL). LIANG, Spencer; Ltd., 26 Compugen, Ltd., 26 Harokmim St , 5885849 Holon (IL). = (54) Title: ANTI-TIGIT ANTIBODIES, ANTI-PVRIG Human PVRIG WT Full length Human PVRIG sequence.starting from position MGHRTLVLPWVIITLCVTAGTPEVVVVIVRMEATELSSETIRCGFLGSGS ANTIBODIES AND COMBINATIONS THEREOF SLVIVSLVGGPNGAGGTTLAVLHPERGIR = - FIG. 1 = = 21- alternative methionine = = = = = OWAPAROARWETOSSISLILEGSGASSPCANTITCCKFASEPEGSWEACGSLPPSSDPGLSAPPTPAPILRADLAGILGV SGVLLFGONLLHIIRRHKHRPAPRLCIPSRTSPQAPRARAWAPSQA (SEQ ID NO: 1) Human . PVRIG sequence starting from position 1 methionine MRTEAQVPALCIPPEPGLEGAMGHRTLVLPWVIITLCVTAGTPEVWVQVRMEATELSSFTIRCGFLGSGSISISTI/SM GPNLJAGG i I LAVLHPERGIRCIWAPARCIARWEIGSSISLILEGSGASSPCANTTFCCKFASEPEGSWEACGSLPPSSDPG = 11 .4 GO CT IN M M 0 --.... 00 1-1 C:::: ) (57) : Anti-PVRIG and anti-TIGIT antibodies ei LSAP PTPAPILRADLAG I LGVSGVLLFGCVYLLH LLRR H ICH RPAPRLOPS RTSPQAPRARAWAPSQA are provided. (SEQ ID NO:2) C [Continued on next page] WO 2018/033798 Al MIDEDIMOMOIDEIREIHRIIMMEIHMODEVOIMIE (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(i)) — as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) — with sequence listing part of description (Rule 5.2(a))
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662376334P | 2016-08-17 | 2016-08-17 | |
US201662376335P | 2016-08-17 | 2016-08-17 | |
US201662417217P | 2016-11-03 | 2016-11-03 | |
US201762477974P | 2017-03-28 | 2017-03-28 | |
US201762513775P | 2017-06-01 | 2017-06-01 | |
US201762513916P | 2017-06-01 | 2017-06-01 | |
US201762513771P | 2017-06-01 | 2017-06-01 | |
US201762538561P | 2017-07-28 | 2017-07-28 | |
PCT/IB2017/001256 WO2018033798A1 (en) | 2016-08-17 | 2017-08-17 | Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201901077RA true SG11201901077RA (en) | 2019-03-28 |
Family
ID=60302413
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201901077RA SG11201901077RA (en) | 2016-08-17 | 2017-08-17 | Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof |
Country Status (25)
Country | Link |
---|---|
US (5) | US10751415B2 (en) |
EP (2) | EP3617232A1 (en) |
JP (2) | JP7068275B2 (en) |
KR (3) | KR20230145510A (en) |
CN (2) | CN112274637A (en) |
AU (1) | AU2017313405A1 (en) |
BR (1) | BR112019003129A2 (en) |
CA (1) | CA3032331A1 (en) |
CL (1) | CL2019000424A1 (en) |
CO (1) | CO2019001980A2 (en) |
CY (1) | CY1122653T1 (en) |
DK (1) | DK3347379T5 (en) |
ES (1) | ES2774320T3 (en) |
HR (1) | HRP20200189T1 (en) |
HU (1) | HUE048313T2 (en) |
IL (2) | IL301682A (en) |
LT (1) | LT3347379T (en) |
MX (3) | MX2019001878A (en) |
MY (1) | MY194032A (en) |
PL (1) | PL3347379T3 (en) |
PT (1) | PT3347379T (en) |
SG (1) | SG11201901077RA (en) |
SI (1) | SI3347379T1 (en) |
UA (1) | UA126802C2 (en) |
WO (1) | WO2018033798A1 (en) |
Families Citing this family (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HRP20221284T1 (en) | 2015-02-19 | 2022-12-23 | Compugen Ltd. | Anti-pvrig antibodies and methods of use |
EP3259597B1 (en) | 2015-02-19 | 2022-04-06 | Compugen Ltd. | Pvrig polypeptides and methods of treatment |
US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
CA3032331A1 (en) * | 2016-08-17 | 2018-02-22 | Compugen Ltd. | Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof |
CA3062061A1 (en) | 2017-05-01 | 2018-11-08 | Agenus Inc. | Anti-tigit antibodies and methods of use thereof |
JP7090347B2 (en) | 2017-05-12 | 2022-06-24 | ハープーン セラピューティクス,インク. | Mesothelin-binding protein |
BR112019025035A2 (en) * | 2017-06-01 | 2020-06-30 | Compugen Ltd. | method to treat cancer |
WO2019062832A1 (en) | 2017-09-29 | 2019-04-04 | 江苏恒瑞医药股份有限公司 | Tigit antibody, antigen-binding fragment thereof, and medical use thereof |
JP2021502330A (en) * | 2017-10-20 | 2021-01-28 | フレッド ハッチンソン キャンサー リサーチ センター | Compositions and immunotherapeutic methods targeting TIGIT and / or CD112R or comprising CD226 overexpression |
JP2021519298A (en) | 2018-03-27 | 2021-08-10 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Real-time monitoring of titers using UV signals |
US20190382477A1 (en) | 2018-06-01 | 2019-12-19 | Compugen Ltd. | Anti-pvrig/anti-tigit bispecific antibodies and methods of use |
KR20210032488A (en) * | 2018-07-20 | 2021-03-24 | 서피스 온콜로지, 인크. | Anti-CD112R compositions and methods |
CN108948182A (en) * | 2018-07-25 | 2018-12-07 | 中国人民解放军第四军医大学 | The application of the anti-alloimmunity rejection of TIGIT-ECD recombinant protein |
AU2019324170A1 (en) | 2018-08-23 | 2021-02-18 | Seagen, Inc. | Anti-TIGIT antibodies |
JP7425049B2 (en) | 2018-09-25 | 2024-01-30 | ハープーン セラピューティクス,インク. | DLL3 binding protein and method of use |
EP3898677A1 (en) | 2018-12-21 | 2021-10-27 | OSE Immunotherapeutics | Bifunctional anti-pd-1/il-7 molecule |
WO2020165374A1 (en) | 2019-02-14 | 2020-08-20 | Ose Immunotherapeutics | Bifunctional molecule comprising il-15ra |
US20220135619A1 (en) | 2019-02-24 | 2022-05-05 | Bristol-Myers Squibb Company | Methods of isolating a protein |
US20220220430A1 (en) | 2019-05-23 | 2022-07-14 | Bristol-Myers Squibb Company | Methods of monitoring cell culture media |
TWI760751B (en) | 2019-05-29 | 2022-04-11 | 美商美國禮來大藥廠 | Tigit and pd-1/tigit-binding molecules |
EP3976832A1 (en) * | 2019-05-30 | 2022-04-06 | Bristol-Myers Squibb Company | Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy |
JP2022537053A (en) * | 2019-06-21 | 2022-08-23 | シングル セル テクノロジー, インコーポレイテッド | Anti-TIGIT antibody |
MX2022000586A (en) * | 2019-07-15 | 2022-03-04 | Shanghai Junshi Biosciences Co Ltd | Anti-tigit antibodies and application thereof. |
KR20220041881A (en) * | 2019-07-29 | 2022-04-01 | 컴퓨젠 엘티디. | Anti-PVRIG antibody formulations and uses thereof |
WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
US11667709B2 (en) | 2019-09-24 | 2023-06-06 | Industrial Technology Research Institute | Anti-TIGIT antibodies and methods of use |
WO2021113831A1 (en) | 2019-12-05 | 2021-06-10 | Compugen Ltd. | Anti-pvrig and anti-tigit antibodies for enhanced nk-cell based tumor killing |
WO2021122866A1 (en) | 2019-12-17 | 2021-06-24 | Ose Immunotherapeutics | Bifunctional molecules comprising an il-7 variant |
CN115003333A (en) * | 2020-03-13 | 2022-09-02 | 江苏恒瑞医药股份有限公司 | PVRIG binding protein and medical application thereof |
CN113563470B (en) * | 2020-04-29 | 2023-02-10 | 广州昂科免疫生物技术有限公司 | Antibody combined with TIGIT antigen and preparation method and application thereof |
US20230258645A1 (en) | 2020-05-07 | 2023-08-17 | Institut Curie | Antxr1 as a biomarker of immunosuppressive fibroblast populations and its use for predicting response to immunotherapy |
PE20231078A1 (en) | 2020-06-02 | 2023-07-17 | Arcus Biosciences Inc | ANTI-TIGIT ANTIBODIES |
TW202200616A (en) | 2020-06-18 | 2022-01-01 | 美商建南德克公司 | Treatment with anti-tigit antibodies and pd-1 axis binding antagonists |
JP2023532768A (en) | 2020-07-07 | 2023-07-31 | バイオエヌテック エスエー | RNA for treatment of HPV-positive cancer |
TW202216778A (en) * | 2020-07-15 | 2022-05-01 | 美商安進公司 | Tigit and cd112r blockade |
US20220065852A1 (en) * | 2020-08-28 | 2022-03-03 | Maxim Biomedical, Inc. | Devices and methods for detecting viral infection |
CN116406369A (en) | 2020-10-05 | 2023-07-07 | 百时美施贵宝公司 | Method for concentrating proteins |
CN112433055A (en) * | 2020-11-04 | 2021-03-02 | 上海药明生物技术有限公司 | Method for detecting biological activity of PVRIG antibody based on reporter gene method |
WO2022112198A1 (en) | 2020-11-24 | 2022-06-02 | Worldwide Innovative Network | Method to select the optimal immune checkpoint therapies |
WO2022111612A1 (en) * | 2020-11-26 | 2022-06-02 | 信达生物制药(苏州)有限公司 | Preparation comprising anti-tigit/pd-1 bispecific antibody, method for preparing same, and use thereof |
WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
TW202245808A (en) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | Therapeutic rna for treating cancer |
WO2022148781A1 (en) | 2021-01-05 | 2022-07-14 | Institut Curie | Combination of mcoln activators and immune checkpoint inhibitors |
WO2022165275A2 (en) | 2021-01-28 | 2022-08-04 | Compugen Ltd. | Combination therapy with anti-pvrig antibodies formulations and anti-pd-1-antibodies |
US20240082397A1 (en) | 2021-01-28 | 2024-03-14 | Compugen Ltd. | Anti-pvrig antibodies formulations and uses thereof |
AU2022219332A1 (en) * | 2021-02-09 | 2023-09-21 | Shanghai Junshi Biosciences Co., Ltd. | Anti-cd112r antibody and use thereof |
WO2022184068A1 (en) * | 2021-03-02 | 2022-09-09 | 百奥泰生物制药股份有限公司 | Application of anti-tigit antibody in treating tumors or cancers |
CN114984227A (en) * | 2021-03-02 | 2022-09-02 | 百奥泰生物制药股份有限公司 | Application of anti-TIGIT antibody in drug combination |
CN115925917A (en) * | 2021-03-08 | 2023-04-07 | 合肥天港免疫药物有限公司 | anti-PVRIG protein antibodies or antibody fragments and uses thereof |
IL307419A (en) | 2021-04-09 | 2023-12-01 | Ose Immunotherapeutics | New scaffold for bifunctional molecules with improved properties |
WO2022214652A1 (en) | 2021-04-09 | 2022-10-13 | Ose Immunotherapeutics | Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains |
CR20230476A (en) | 2021-04-30 | 2024-01-30 | Medimmune Llc | Bispecific pd-1 and tigit binding proteins and uses therof |
AR125753A1 (en) | 2021-05-04 | 2023-08-09 | Agenus Inc | ANTI-TIGIT ANTIBODIES, ANTI-CD96 ANTIBODIES AND METHODS OF USE OF THESE |
WO2022242663A1 (en) * | 2021-05-18 | 2022-11-24 | Suzhou Kanova Biopharmaceutical Co., Ltd. | Anti-tigit antibodies and their use |
CN115466327A (en) * | 2021-06-10 | 2022-12-13 | 北京天广实生物技术股份有限公司 | Antibodies that bind to TIGIT and uses thereof |
CN115010800A (en) * | 2021-06-10 | 2022-09-06 | 百奥赛图(北京)医药科技股份有限公司 | Construction method and application of PVRIG gene humanized non-human animal |
AU2022304943A1 (en) * | 2021-07-02 | 2024-01-18 | Laekna Therapeutics Shanghai Co., Ltd. | Depletion of activated hepatic stellate cells (hscs) and uses thereof |
WO2023285552A1 (en) | 2021-07-13 | 2023-01-19 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer |
WO2023010094A2 (en) | 2021-07-28 | 2023-02-02 | Genentech, Inc. | Methods and compositions for treating cancer |
CN117751143A (en) * | 2021-07-30 | 2024-03-22 | 山东先声生物制药有限公司 | anti-PVRIG/anti-TIGIT bispecific antibodies and uses |
AU2022327511A1 (en) * | 2021-08-09 | 2024-03-07 | Biotheus Inc. | Anti-tigit antibody and use thereof |
WO2023040940A1 (en) * | 2021-09-15 | 2023-03-23 | 江苏恒瑞医药股份有限公司 | Use of pvrig/tigit binding protein in combination with immune checkpoint inhibitor in treatment of cancers |
WO2023040935A1 (en) * | 2021-09-15 | 2023-03-23 | 江苏恒瑞医药股份有限公司 | Pharmaceutical composition comprising anti-pvrig/tigit bispecific antibody |
TW202328195A (en) | 2021-09-15 | 2023-07-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | Proteins that specifically bind to pd-1 and the pharmaceutical use thereof |
CN115838424A (en) * | 2021-09-22 | 2023-03-24 | 上海康岱生物医药技术股份有限公司 | Monoclonal antibody targeting TIGIT |
WO2023056403A1 (en) | 2021-09-30 | 2023-04-06 | Genentech, Inc. | Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists |
TW202333802A (en) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | Therapeutic rna for lung cancer |
CN116355095A (en) * | 2021-12-27 | 2023-06-30 | 上海健信生物医药科技有限公司 | Antibodies and bispecific antibodies targeting TIGIT and uses thereof |
WO2023137161A1 (en) * | 2022-01-14 | 2023-07-20 | Amgen Inc. | Triple blockade of tigit, cd112r, and pd-l1 |
WO2023149978A1 (en) * | 2022-02-04 | 2023-08-10 | Mereo Biopharma 5, Inc. | Cancer biomarkers and cancer treatments |
WO2023161448A1 (en) * | 2022-02-24 | 2023-08-31 | Abnomx Bv | Human-like target-binding proteins |
WO2023173011A1 (en) | 2022-03-09 | 2023-09-14 | Bristol-Myers Squibb Company | Transient expression of therapeutic proteins |
WO2023215719A1 (en) | 2022-05-02 | 2023-11-09 | Arcus Biosciences, Inc. | Anti-tigit antibodies and uses of the same |
WO2023230532A1 (en) * | 2022-05-26 | 2023-11-30 | Compugen Ltd. | Anti-tigit antibody formulation |
WO2023240058A2 (en) | 2022-06-07 | 2023-12-14 | Genentech, Inc. | Prognostic and therapeutic methods for cancer |
WO2023236980A1 (en) * | 2022-06-08 | 2023-12-14 | 山东先声生物制药有限公司 | Pharmaceutical composition of pvrig/tigit bispecific antibody and use thereof |
WO2024003360A1 (en) | 2022-07-01 | 2024-01-04 | Institut Curie | Biomarkers and uses thereof for the treatment of neuroblastoma |
WO2024028386A1 (en) | 2022-08-02 | 2024-02-08 | Ose Immunotherapeutics | Multifunctional molecule directed against cd28 |
WO2024032700A1 (en) * | 2022-08-10 | 2024-02-15 | Beigene, Ltd. | Anti-pvrig antibodies and methods of use |
Family Cites Families (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
US7368531B2 (en) | 1997-03-07 | 2008-05-06 | Human Genome Sciences, Inc. | Human secreted proteins |
WO1998048032A2 (en) | 1997-04-21 | 1998-10-29 | Donlar Corporation | POLY-(α-L-ASPARTIC ACID), POLY-(α-L-GLUTAMIC ACID) AND COPOLYMERS OF L-ASP AND L-GLU, METHOD FOR THEIR PRODUCTION AND THEIR USE |
EP2386574A3 (en) | 1999-01-15 | 2012-06-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
WO2000052151A2 (en) | 1999-03-05 | 2000-09-08 | Incyte Pharmaceuticals, Inc. | Human secretory proteins |
US20030224379A1 (en) | 2000-01-21 | 2003-12-04 | Tang Y. Tom | Novel nucleic acids and polypeptides |
US7449443B2 (en) | 2000-03-23 | 2008-11-11 | California Institute Of Technology | Method for stabilization of proteins using non-natural amino acids |
US6586207B2 (en) | 2000-05-26 | 2003-07-01 | California Institute Of Technology | Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues |
KR100988949B1 (en) | 2001-10-25 | 2010-10-20 | 제넨테크, 인크. | Glycoprotein compositions |
AU2003248370A1 (en) | 2002-02-27 | 2003-09-09 | California Institute Of Technology | Computational method for designing enzymes for incorporation of amino acid analogs into proteins |
WO2003085107A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Cells with modified genome |
EP2277532A1 (en) | 2002-09-11 | 2011-01-26 | Genentech, Inc. | Novel composition and methods for the treatment of immune related diseases |
CA2500687A1 (en) | 2002-10-02 | 2004-04-15 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
AU2003290432A1 (en) | 2002-12-26 | 2004-07-22 | Asahi Kasei Pharma Corporation | T cell activating gene |
WO2005019258A2 (en) | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
EP1675620B1 (en) | 2003-10-09 | 2019-05-08 | Ambrx, Inc. | Polymer derivatives |
US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
GB2429207A (en) | 2004-02-02 | 2007-02-21 | Ambrx Inc | Modified human interferon polypeptides and their uses |
TWI380996B (en) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | Anti-ox40l antibodies |
US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
PT2343320T (en) | 2005-03-25 | 2018-01-23 | Gitr Inc | Anti-gitr antibodies and uses thereof |
ES2609429T3 (en) | 2005-05-12 | 2017-04-20 | Zymogenetics, Inc. | Compositions and methods to modulate immune responses |
EP2007806A2 (en) | 2006-04-13 | 2008-12-31 | ZymoGenetics, Inc. | Tetramerizing polypeptides and methods of use |
CA2648915A1 (en) | 2006-04-13 | 2007-11-01 | Zymogenetics, Inc. | Tetramerizing polypeptides and methods of use |
CA2660286A1 (en) | 2006-08-09 | 2008-02-21 | Homestead Clinical Corporation | Organ-specific proteins and methods of their use |
RU2009117237A (en) | 2006-10-06 | 2010-11-20 | Такеда Фармасьютикал Компани Лимитед (Jp) | CANCER PREVENTION / TREATMENT |
CA3179151A1 (en) | 2008-04-09 | 2009-10-15 | Genentech, Inc. | Novel compositions and methods for the treatment of immune related diseases |
AR072999A1 (en) | 2008-08-11 | 2010-10-06 | Medarex Inc | HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE |
CA2745961A1 (en) | 2008-12-04 | 2010-06-10 | The Regents Of The University Of California | Materials and methods for determining diagnosis and prognosis of prostate cancer |
SG196798A1 (en) | 2008-12-09 | 2014-02-13 | Genentech Inc | Anti-pd-l1 antibodies and their use to enhance t-cell function |
JP5782385B2 (en) | 2009-02-17 | 2015-09-24 | ユーシービー ファーマ ソシエテ アノニム | Antibody molecule having specificity for human OX40 |
WO2011014438A1 (en) | 2009-07-31 | 2011-02-03 | N.V. Organon | Fully human antibodies to btla |
TW201132813A (en) | 2010-03-03 | 2011-10-01 | Koo Foundation Sun Yat Sen Cancer Ct | Methods for classifying and treating breast cancers |
KR101958753B1 (en) | 2010-04-13 | 2019-03-15 | 셀덱스 쎄라퓨틱스, 인크. | Antibodies that bind human cd27 and uses thereof |
US20120213771A1 (en) | 2010-04-13 | 2012-08-23 | Celldex Therapeutics Inc. | Antibodies that bind human cd27 and uses thereof |
US20140045915A1 (en) | 2010-08-31 | 2014-02-13 | The General Hospital Corporation | Cancer-related biological materials in microvesicles |
SG10201506906VA (en) | 2010-09-09 | 2015-10-29 | Pfizer | 4-1bb binding molecules |
US8962804B2 (en) | 2010-10-08 | 2015-02-24 | City Of Hope | Meditopes and meditope-binding antibodies and uses thereof |
WO2012129488A2 (en) | 2011-03-23 | 2012-09-27 | Virginia Commonwealth University | Gene signatures associated with rejection or recurrence of cancer |
WO2012156515A1 (en) | 2011-05-18 | 2012-11-22 | Rheinische Friedrich-Wilhelms-Universität Bonn | Molecular analysis of acute myeloid leukemia |
EP2723924A4 (en) | 2011-06-22 | 2015-03-25 | Oncocyte Corp | Methods and compositions for the treatment and diagnosis of cancer |
US8841418B2 (en) | 2011-07-01 | 2014-09-23 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to TIM3 |
AU2013271515A1 (en) | 2012-06-06 | 2015-01-15 | Oncomed Pharmaceuticals, Inc. | Binding agents that modulate the Hippo pathway and uses thereof |
CN103073644B (en) * | 2012-12-31 | 2014-03-12 | 中国科学技术大学 | Specific anti-mouse TIGIT monoclonal antibody and preparation method, identification and application thereof |
UA118750C2 (en) | 2013-03-15 | 2019-03-11 | Ґлаксосмітклайн Інтеллектуал Проперті Дивелопмент Лімітед | Anti-lag-3 binding proteins |
US9873740B2 (en) * | 2013-07-16 | 2018-01-23 | Genentech, Inc. | Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors |
WO2016013433A1 (en) | 2014-07-23 | 2016-01-28 | 株式会社Ihi | PRODUCTION METHOD FOR Ni ALLOY COMPONENT |
JO3663B1 (en) | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | Anti-lag3 antibodies and antigen-binding fragments |
EA036311B1 (en) | 2014-08-19 | 2020-10-26 | Мерк Шарп И Доум Корп. | Anti-tigit antibodies |
MX2017006323A (en) | 2014-11-21 | 2017-08-21 | Bristol Myers Squibb Co | Antibodies comprising modified heavy constant regions. |
BR112017013385A2 (en) | 2014-12-23 | 2018-02-06 | Bristol-Myers Squibb Company | antibodies to tigit |
HRP20221284T1 (en) | 2015-02-19 | 2022-12-23 | Compugen Ltd. | Anti-pvrig antibodies and methods of use |
EP3259597B1 (en) | 2015-02-19 | 2022-04-06 | Compugen Ltd. | Pvrig polypeptides and methods of treatment |
CN107922484A (en) | 2015-03-06 | 2018-04-17 | 索伦托治疗有限公司 | With reference to the Antybody therapy agent of TIM3 |
US20180044429A1 (en) | 2015-03-09 | 2018-02-15 | Celldex Therapeutics, Inc. | Cd27 agonists |
TWI715587B (en) | 2015-05-28 | 2021-01-11 | 美商安可美德藥物股份有限公司 | Tigit-binding agents and uses thereof |
WO2016196389A1 (en) | 2015-05-29 | 2016-12-08 | Bristol-Myers Squibb Company | Treatment of renal cell carcinoma |
JO3620B1 (en) | 2015-08-05 | 2020-08-27 | Amgen Res Munich Gmbh | Immune-checkpoint inhibitors for use in the treatment of blood-borne cancers cancers |
CA2997179A1 (en) | 2015-09-02 | 2017-03-09 | The Regents Of The Unversity Of Colorado, A Body Corporate | Compositions and methods for modulating t-cell mediated immune response |
BR112018005862A2 (en) | 2015-09-25 | 2018-10-16 | Genentech, Inc. | antibodies, isolated antibodies, polynucleotide, vector, host cell, antibody production method, immunoconjugate, composition, uses of antibodies, methods for treating or retarding the progression of a cancer and a disease and for increasing, enhancing or stimulating a response or immune function and kit |
UA125062C2 (en) | 2015-10-01 | 2022-01-05 | Потенза Терапеутікс, Інк. | ANTI-TIGIT ANTIGEN-BINDING PROTEINS AND METHODS OF THEIR APPLICATION |
WO2018017864A2 (en) | 2016-07-20 | 2018-01-25 | Oncomed Pharmaceuticals, Inc. | Pvrig-binding agents and uses thereof |
CA3032331A1 (en) * | 2016-08-17 | 2018-02-22 | Compugen Ltd. | Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof |
BR112019025035A2 (en) * | 2017-06-01 | 2020-06-30 | Compugen Ltd. | method to treat cancer |
-
2017
- 2017-08-17 CA CA3032331A patent/CA3032331A1/en active Pending
- 2017-08-17 PT PT177974292T patent/PT3347379T/en unknown
- 2017-08-17 LT LTEP17797429.2T patent/LT3347379T/en unknown
- 2017-08-17 WO PCT/IB2017/001256 patent/WO2018033798A1/en active Application Filing
- 2017-08-17 KR KR1020237033526A patent/KR20230145510A/en not_active Application Discontinuation
- 2017-08-17 EP EP19199752.7A patent/EP3617232A1/en active Pending
- 2017-08-17 AU AU2017313405A patent/AU2017313405A1/en active Pending
- 2017-08-17 PL PL17797429T patent/PL3347379T3/en unknown
- 2017-08-17 US US15/680,187 patent/US10751415B2/en active Active
- 2017-08-17 MX MX2019001878A patent/MX2019001878A/en unknown
- 2017-08-17 CN CN202011070171.3A patent/CN112274637A/en active Pending
- 2017-08-17 UA UAA201902564A patent/UA126802C2/en unknown
- 2017-08-17 KR KR1020227009297A patent/KR102585976B1/en active IP Right Grant
- 2017-08-17 EP EP17797429.2A patent/EP3347379B9/en active Active
- 2017-08-17 ES ES17797429T patent/ES2774320T3/en active Active
- 2017-08-17 DK DK17797429.2T patent/DK3347379T5/en active
- 2017-08-17 HU HUE17797429A patent/HUE048313T2/en unknown
- 2017-08-17 IL IL301682A patent/IL301682A/en unknown
- 2017-08-17 IL IL264654A patent/IL264654B2/en unknown
- 2017-08-17 MY MYPI2019000633A patent/MY194032A/en unknown
- 2017-08-17 BR BR112019003129A patent/BR112019003129A2/en unknown
- 2017-08-17 SG SG11201901077RA patent/SG11201901077RA/en unknown
- 2017-08-17 SI SI201730157T patent/SI3347379T1/en unknown
- 2017-08-17 JP JP2019508853A patent/JP7068275B2/en active Active
- 2017-08-17 KR KR1020197006497A patent/KR102450208B1/en active IP Right Grant
- 2017-08-17 CN CN201780050131.2A patent/CN110088132B/en active Active
- 2017-10-26 US US15/795,135 patent/US10124061B2/en active Active
-
2018
- 2018-03-27 US US15/937,784 patent/US10213505B2/en active Active
-
2019
- 2019-02-15 MX MX2021006235A patent/MX2021006235A/en unknown
- 2019-02-15 CL CL2019000424A patent/CL2019000424A1/en unknown
- 2019-02-15 MX MX2021006237A patent/MX2021006237A/en unknown
- 2019-02-28 CO CONC2019/0001980A patent/CO2019001980A2/en unknown
-
2020
- 2020-02-05 CY CY20201100108T patent/CY1122653T1/en unknown
- 2020-02-05 HR HRP20200189TT patent/HRP20200189T1/en unknown
- 2020-06-17 US US16/904,511 patent/US11701424B2/en active Active
-
2022
- 2022-04-28 JP JP2022074196A patent/JP2022115922A/en active Pending
-
2023
- 2023-05-23 US US18/322,545 patent/US20240075137A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201901077RA (en) | Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof | |
SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
SG11201807573VA (en) | Methods for providing single-stranded rna | |
SG11201903514VA (en) | Novel cd47 monoclonal antibodies and uses thereof | |
SG11201807912SA (en) | Vaccine against rsv | |
SG11201810179RA (en) | Novel crispr enzymes and systems | |
SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
SG11201906695VA (en) | Universal bchain e3a connections (ubec) | |
SG11201807252QA (en) | Anti-lag-3 antibodies | |
SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
SG11201909011PA (en) | Niraparib compositions | |
SG11201909432SA (en) | Compounds for increasing genome editing efficiency | |
SG11201808709VA (en) | T cell receptors | |
SG11201900447SA (en) | Methods and compositions for modifying genomic dna | |
SG11201807705RA (en) | Directional lock for interface headgear arrangement | |
SG11201901206SA (en) | Trimer stabilizing hiv envelope protein mutations | |
SG11201403106SA (en) | Anti-phf-tau antibodies and their uses | |
SG11201806639VA (en) | New streptococcal proteases | |
SG11201803593QA (en) | Engineered nucleic-acid targeting nucleic acids | |
SG11201901351UA (en) | A patient interface, system and method | |
SG11201806393QA (en) | Use of gabaa receptor modulators for treatment of itch | |
SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same | |
SG11201810429UA (en) | Anti-cd19 antibody formulations | |
SG11201908325PA (en) | Process for the preparation of glucuronide drug-linkers and intermediates thereof | |
SG11201805649UA (en) | Therapeutic anti-cd9 antibody |